Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NYU Langone Health
With
Genzyme, a Sanofi Company
Gaucher disease is a potential secondary cause of low bone mineral density and it is prevalent among patients with low BMD. This cross sectional design study will measure point prevalence of Gaucher disease in patients with low bone mineral density (BMD).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients \> or equal to18 years and able to provide written consent.
Patients who have had a bone density test demonstrating T-score \<-1.0 on a DEXA scan within the past year or those who are prospectively referred for DEXA scan and who are later identified by their physician to have a DEXA T-score \< -1.0.
You may not be if
Subject unable to read and sign consent form.
Terminally ill subjects or subjects with serious co-morbidities (malignancy), which would limit the ability of the patient to participate in the study.
Subjects with the following disorders or exposures
Underlying skeletal dysplasia
An endocrinologic/metabolic disease known to cause bone demineralization: including parathyroid dysfunction, hyperthyroidism, Cushing syndrome, hypogonadism, panhypopituitarism
Cystic Fibrosis
Exposure to medications that are known to cause low BMD including chemotherapy within past 2 years, chronic corticosteroid or phenytoin use within past 2 years
Radiation exposure within the past 5 years
Subjects previously diagnosed with Gaucher Disease
Clareo Health | Genzyme Osteopenia/Osteoporosis Study
